Preliminary observations suggest that chromium may potentiate antidepressant pharmacotherapy for dysthymic disorder. A 33-year-old white woman presented with weight loss, anemia, thrombocytopenia, hemolysis, liver dysfunction (aminotransferase enzymes 1520 times normal, total bilirubin 3 times normal), and renal failure (serum creatinine 5.3 mg/dL blood urea nitrogen 152 mg/dL). Nevertheless, it does not affect liver enzymes. Single-blind substitution of other dietary supplements in each of the patients demonstrated specificity of response to chromium supplementation. Discussion and conclusion: This study showed that consuming 400 µg/day of CrPic for 12 weeks in patients with NAFLD causes a significant change in leptin, adiponectin, oxidative stress (expect glutathione peroxidase), and body weight, compared to baseline.
#Chromium polynicotinate and acarbose series
In a series of 5 patients, chromium supplementation led to remission of dysthymic symptoms.
Compared with the study of major depression, there has been little systematic study of potentiation strategies for antidepressant-refractory dysthymic disorder.įollowing a patient's report of dramatic response to the addition of chromium supplementation to sertraline pharmacotherapy for dysthymic disorder (DSM-IV), the authors initiated a series of single-blind and open-label trials of chromium picolinate or chromium polynicotinate in the treatment of antidepressant-refractory dysthymic disorder. Dysthymic disorder is a relatively common illness that is often treated with antidepressants.
0 kommentar(er)
